🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Generalized Myasthenia Gravis

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod NCT07072988Phase 49 sites📍 Nice📍 Créteil📍 Garches Centre Hospitalier Universitaire de Nice · Tests: Efgartigimod Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) NCT07215650Phase 110 sites📍 Fuzhou📍 Guangzhou📍 Guangzhou Candid Therapeutics · Tests: Cizutamig A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy NCT07595653n/a30 sites📍 Acquaviva delle Fonti📍 Ancona📍 Bari argenx A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. NCT06447597Phase 2, Phase 318 sites📍 Beijing📍 Changchun📍 Changsha Shanghai Jiaolian Drug Research and Development Co., Ltd · Tests: B007, Placebo A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis NCT07250750Phase 1, Phase 225 sites📍 Altamonte Springs📍 Boca Raton📍 Naples ImmunAbs Inc. · Tests: IM-101 Part A, Placebo Part A, IM-101 Part B, Placebo Part B AXIS MG Patient Registry NCT07761026n/a1 site📍 Framingham Autoimmune Neurology Alliance Myasthenia Gravis Foundation of America Global MG Patient Registry NCT06617741n/a1 site📍 Westborough Myasthenia Gravis Foundation of America PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis NCT06607627Phase 313 sites📍 Washington D.C.📍 Norfolk📍 Joinville Alexion Pharmaceuticals, Inc. · Tests: Gefurulimab A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis NCT04951622Phase 3112 sites📍 Paradise Valley📍 Scottsdale📍 Los Angeles Janssen Research & Development, LLC · Tests: Nipocalimab, Placebo, Nipocalimab SC-LIV Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab) NCT07570589n/a11 sites📍 Nice📍 Angers📍 Boulogne-sur-Mer Centre Hospitalier Universitaire de Nice · Tests: Patients diagnosed with generalized myasthenia gravis and treated with Rozanolixizumab Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia NCT07247279n/a7 sites📍 Kazan'📍 Moscow📍 Novosibirsk AstraZeneca ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis NCT07294170n/a37 sites📍 Carlsbad📍 Miami📍 Miami argenx · Tests: Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis NCT06392386Phase 2, Phase 322 sites📍 Charlotte📍 Denton📍 Charlottesville argenx · Tests: Efgartigimod PH20 SC A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) NCT06909214Phase 418 sites📍 La Jolla📍 Rancho Mirage📍 Boca Raton argenx · Tests: Efgartigimod PH20 SC Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis NCT06064695NA2 sites📍 Fairway📍 Columbia University of Missouri-Columbia · Tests: Whole-body Electrical Muscle Stimulation Exercise A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) NCT06987539Phase 214 sites📍 Chicago📍 Philadelphia📍 Austin Amgen · Tests: Inebilizumab Study of Ultomiris® (Ravulizumab) Safety in Pregnancy NCT06312644n/a7 sites📍 Boston📍 Melbourne📍 Paris Alexion Pharmaceuticals, Inc. · Tests: Ultomiris Markers of Favorable Response to Complement Inhibitors Therapy NCT06455709n/a1 site📍 Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis NCT07673627Phase 28 sites📍 Carlsbad📍 Miami📍 Las Vegas argenx · Tests: Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab NCT07221838Phase 412 sites📍 Chicago📍 Schaumburg📍 Neptune City Alexion Pharmaceuticals, Inc. · Tests: Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis NCT07622342Phase 22 sites📍 Changsha📍 Shanghai Guangdong Hengrui Pharmaceutical Co., Ltd · Tests: SHR-2173 injection, SHR-2173 injection, Placebo A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) NCT07647510Phase 312 sites📍 Pasadena📍 Boca Raton📍 Fayetteville Dianthus Therapeutics · Tests: Claseprubart, Placebo, Claseprubart, Placebo ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod NCT07284420Phase 233 sites📍 Carlsbad📍 Miami📍 Tampa argenx · Tests: Efgartigimod IV, Empasiprubart IV Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases NCT06626919Phase 114 sites📍 Los Angeles📍 Orange📍 Palo Alto Kite, A Gilead Company · Tests: anito-cel, Cyclophosphamide, Fludarabine Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis NCT07411963n/a8 sites📍 Nice📍 Bron📍 Garches Centre Hospitalier Universitaire de Nice · Tests: early use of Ravulizumab RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis NCT06359041Phase 1, Phase 217 sites📍 Orange📍 Sacramento📍 San Francisco Cabaletta Bio · Tests: CABA-201, CABA-201 Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis NCT06967480n/a23 sites📍 Bergamo📍 Bologna📍 Bologna Alexion Pharmaceuticals, Inc. · Tests: Ravulizumab Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) NCT07596784Phase 310 sites📍 Beijing📍 Changchun📍 Fuzhou Alexion Pharmaceuticals, Inc. · Tests: Ravulizumab Study of Aritinercept in Patients With Generalized Myasthenia Gravis NCT07596901Phase 1, Phase 211 sites📍 Pasadena📍 Altamonte Springs📍 Boca Raton Aurinia Pharmaceuticals Inc. · Tests: Aritinercept, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy